Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records

Abstract: Introduction: Effects of cariprazine on weight and metabolic parameters were evaluated. Methods: Analyses based on Optum Humedica electronic health records data from October 1, 2014—December 31, 2020. Primary objective was to estimate bodyweight trajectories in overall patient cohort and in subgroups over 12-month period before cariprazine (baseline), up to 12-months following cariprazine initiation. Secondary objectives were change in hemoglobin A1c (HbA1c), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and discontinuation rates for metabolic regulating comedications. Results: 2,301 patients met inclusion criteria; average follow-up duration was 133.7 days. Across timepoints, average weight increase for patients starting cariprazine was +0.8 kg (n=811), +1.1 kg (n=350),and +1.4 kg (n=107) at months 3, 6,and 12, respectively. Average HbA1c levels (n=189) increased during baseline (+0.15%/year) and decreased after starting cariprazine (-0.21%/year). Average triglyceride levels (n=257) increased during baseline (+14.98 mg/dL/year) and decreased after starting cariprazine (-0.69 mg/dL/year). LDL (n=247) and HDL (n=255) values decreased during baseline (-7.34 and -1.06 mg/dL/year, respectively); after starting cariprazine, LDL increased +5.64mg/dL/year and HDL decreased -0.64 mg/dL/year relative to baseline. Shifts from normal/borderline to high levels of total cholesterol (